AstraZeneca PACKAGE/LABEL PRINCIPAL DISPLAY PANEL 5 mg/500 mg 30 Tablets NDC 0310-6250-30 xigduo XR (dapagliflozin/metformin HCl extended-release) tablets 5 mg/500 mg Dispense with Medication Guide Rx only Do not crush, cut, or chew tablets
Contact the Clinical Advisory Team with the target sequence, required purity, and intended assay context
Clear Pricing With No Surprise Add-Ons The best online GLP-1 programs tell you exactly what you will pay each month, including medication, before you hand over a credit card
Given the commercial scale of the obesity market, AstraZeneca is one of several large pharma players betting that the oral delivery format will be the dominant paradigm within a decade
Meanwhile these agents have the potential to reduce major adverse cardiovascular events (MACE) in patient with T2DM as a drug class, individual drugs have different potency and effects they need tailored approach to align with patient treatment goals rather than generalized use (117)
How quickly these approaches mature will help determine whether GLP-1s become a sustainable part of the benefits landscapeor remain a flashpoint in the fight over drug affordability
